Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Abstract Background Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk,...

Full description

Bibliographic Details
Main Authors: Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Epidemiology
Sodium glucose transporter 2 inhibitors
Glucagon‐like peptide-1 receptor agonist
Mortality
Cardiovascular disease
Online Access:https://doi.org/10.1186/s12933-021-01258-x

Internet

https://doi.org/10.1186/s12933-021-01258-x

Similar Items